Form 4: Ionis Pharmaceuticals Director Spencer R. Berthelsen Reports Stock Vesting

Director Spencer R. Berthelsen reports the vesting of restricted stock units into Ionis Pharmaceuticals common stock.

Summary

• On July 15, 2024, Spencer R. Berthelsen, a director of Ionis Pharmaceuticals, acquired 4,677 shares of common stock due to the vesting of restricted stock units (RSUs).
• The RSUs vested and were released at a price of $0.0.
• Following the transaction, Berthelsen directly owns 151,934 shares of Ionis Pharmaceuticals common stock.
• Berthelsen also indirectly owns 70 shares through his daughter, but disclaims beneficial ownership of these shares.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to stock transactions, and does not inherently convey positive or negative sentiment.

Positives

• The vesting of RSUs indicates a continued alignment of the director's interests with those of the shareholders.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance.

Industry Context

This Form 4 filing is a routine disclosure related to executive compensation and stock ownership, common in the pharmaceutical industry.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment due to the director's increased stake in the company.

Key Dates